Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) marched up 36.22% compared to a 52-week low price of $1.85. The shares were last seen trading 2.86% higher, taking the closing price at $2.52 on 01/10/2019. At recent session, the prices were hovering between $2.4 and $2.55. This company shares are 224.21% off its target price of $8.17 and the current market capitalization stands at $258.66M. The recent change has given its price a -3.35% deficit over SMA 50 and -38.24% deficit over its 52-week high. The stock witnessed 7.23% gains, -25.22% declines and -21.74% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CPRX’s volatility during a week at 5.61% and during a month it has been found around 7.9%.Catalyst Pharmaceuticals, Inc. (CPRX) Top Holders
Institutional investors currently hold around $125 million or 49.8% in CPRX stock. Look at its top three institutional owners. Blackrock Inc. owns $15.32 million in Catalyst Pharmaceuticals, Inc., which represents roughly 5.92% of the company’s market cap and approximately 12.25% of the institutional ownership. Similar statistics are true for the second largest owner, Consonance Capital Management Lp, which owns 6,044,719 shares of the stock are valued at $14.81 million. The third largest holder is Broadfin Capital, Llc, which currently holds $12.58 million worth of this stock and that ownership represents nearly 4.87% of its market capitalization.Catalyst Pharmaceuticals, Inc. 13F Filings
At the end of September reporting period, 48 institutional holders increased their position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by some 3,259,203 shares, 39 decreased positions by 6,187,384 and 23 held positions by 41,734,562. That puts total institutional holdings at 51,181,149 shares, according to SEC filings. The stock grabbed 12 new institutional investments totaling 1,464,101 shares while 14 institutional investors sold out their entire positions totaling 982,865 shares.Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Trades
Multiple company employees have indulged in significant insider trading. Catalyst Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Denkhaus Donald A has acquired 25,000 shares of Catalyst Pharmaceuticals, Inc. (CPRX) in trading session dated Dec. 27, 2018. These shares are worth $47,750 and were traded at $1.91 each. The SEC filing shows that Mcenany Patrick J performed a purchase of 20,000 shares. The President and CEO added these shares by way of transaction on Dec. 19, 2018. The company’s shares were assimilated at $2.24 per share worth to an investment of some $44,800 on account of Mcenany Patrick J.
Director, Denkhaus Donald A, purchased 60,000 common shares of Catalyst Pharmaceuticals, Inc. (CPRX) in the open market. In a transaction dated Dec. 14, 2018, the shares were bought at an average price of $2.48, giving away a sum of $148,800. After this purchase, 200,000 common shares of CPRX are directly owned by the insider, with total stake valued at $504,000.
In the transaction dated Dec. 14, 2018, the great number of shares acquired came courtesy the Director; O’Keeffe Charles B added a total of 20,000 shares at an average price of $2.5, amounting to approximately $50,000. The insider now directly owns 543,376 shares worth $1,369,308.Catalyst Pharmaceuticals, Inc. (CPRX) Analyst Guide
Several analysts have released their opinion on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.83 average brokerage recommendation.